• Structural Insights into the Nipah Virus Polymerase Complex

  2026-05-09

  This study presents high-resolution structures of the Nipah virus L-P polymerase complex, revealing the molecular organization and interactions critical for viral replication. The findings provide a structural basis for antiviral targeting, advancing understanding of paramyxovirus replication mechanisms.

• HyperScript III RT SuperMix: Precision in Gene Expression qP

  2026-05-08

  HyperScript III RT SuperMix for qPCR (with gDNA wiper) empowers high-fidelity reverse transcription from challenging RNA samples, including low-concentration and high-GC content inputs. Its integrated genomic DNA removal and optimized primer balance streamline two-step qRT-PCR for sensitive, reproducible gene expression analysis, elevating both clinical and translational research.

• TCF25 Orchestrates Lysosomal Acidification and Cell Fate in

  2026-05-08

  Ren et al. (2025) reveal that TCF25 acts as a nutrient sensor, enhancing lysosomal acidification via V-ATPase to regulate metabolic adaptation and lysosome-dependent cell death during glucose starvation. This work identifies a new axis connecting nutrient sensing, autophagy, and cell death, with implications for metabolic and ischemic disorders.

• Bafilomycin A1: Precision V-ATPase Inhibitor for Lysosomal R

  2026-05-07

  Bafilomycin A1 empowers researchers to dissect lysosomal function and intracellular pH regulation with unmatched specificity and nanomolar potency. This guide details best-practice protocols, advanced workflow integrations, and troubleshooting strategies, mapping evidence from both foundational and emerging studies.

• CAY10499: Inhibitor of Human Hormone Sensitive Lipase for Li

  2026-05-07

  CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, is transforming lipid metabolism research by enabling precise, reproducible enzyme inhibition in complex cellular and biochemical assays. Its selectivity and robust performance make it indispensable for dissecting pathways in steroidogenesis, adipose tissue function, and atherosclerosis.

• Scalable EPSC-iMSC EV Biomanufacturing for Regenerative Ther

  2026-05-06

  Gong et al. present an automated, high-yield platform for producing extracellular vesicles (EVs) from induced mesenchymal stem cells (iMSCs) derived from extended pluripotent stem cells (EPSCs). This strategy overcomes major limitations of donor variability and scalability in EV therapeutics, enabling standardized large-scale EV production with demonstrated efficacy in pulmonary fibrosis models.

• S Tag Peptide: Practical Guidelines for Fusion Tag Applicati

  2026-05-06

  S Tag Peptide addresses solubility and detection challenges in recombinant protein workflows, making it suitable for projects requiring robust antibody-based detection and affinity purification. It is not recommended for applications needing ethanol solubility or standalone enzymatic activity.

• Macrophage EV miR-660 Drives Breast Cancer Metastasis via NF

  2026-05-05

  This study uncovers how tumor-associated macrophage-derived extracellular vesicles (EVs) containing microRNA-660 accelerate breast cancer progression. By demonstrating that miR-660 targets KLHL21 to activate the IKKβ/NF-κB p65 signaling pathway, the research highlights a novel mechanism of metastatic regulation with potential therapeutic implications.

• Concanamycin A: Precision V-type H+-ATPase Inhibitor in Canc

  2026-05-05

  Concanamycin A stands out as a nanomolar V-type H+-ATPase inhibitor, enabling researchers to dissect endosomal acidification and apoptosis pathways in tumor cells with precision. This article guides advanced users through optimized protocols, experimental troubleshooting, and the latest insights from nutrient sensing studies to maximize the impact of Concanamycin A in translational cancer research.

• Naftifine HCl: Mechanistic Innovation for Translational Anti

  2026-05-04

  This thought-leadership article unpacks the mechanistic foundation and translational potential of Naftifine HCl, an allylamine antifungal agent targeting squalene 2,3-epoxidase. Drawing from recent muscle biology signaling insights and competitive antifungal research, we provide strategic guidance for experimentalists and position Naftifine HCl as a high-purity, research-grade tool for advancing mycology and membrane biology.

• Y-27632 Dihydrochloride: Precision ROCK Inhibition in Neuro-

  2026-05-04

  Explore how Y-27632 dihydrochloride, a potent ROCK inhibitor, unlocks new frontiers in modeling neuro-epithelial interactions and stem cell viability. This in-depth guide details advanced applications, assay design, and crucial innovations from recent microfluidic studies.

• SCH772984 HCl: Precision ERK1/2 Inhibition in Cancer Models

  2026-05-03

  SCH772984 HCl is redefining cancer and stem cell research as a potent, selective ERK1/2 inhibitor. Its nanomolar efficacy and robust inhibition of MAPK signaling deliver reproducible results in BRAF- and RAS-mutant tumor models—even in the face of adaptive resistance.

• Nocodazole: Driving Translational Microtubule and DNA Repair

  2026-05-02

  This thought-leadership article explores Nocodazole’s unique value as a reversible microtubule polymerization inhibitor, dissecting its mechanistic utility in microtubule dynamics, cell cycle regulation, and DNA damage bypass studies. Integrating recent findings on chromatin remodeling and referencing leading literature, it provides strategic and protocol-level guidance for translational researchers seeking to accelerate cancer research and anticancer drug evaluation. The article also distinguishes itself by bridging mechanistic insights with practical assay design, surpassing typical product-centric content.

• Ruxolitinib Phosphate: Advanced Insights into JAK/STAT Modul

  2026-05-01

  Explore the molecular mechanisms and innovative research applications of Ruxolitinib phosphate (INCB018424) in JAK/STAT pathway modulation. This article offers a unique, in-depth analysis of its role in apoptosis, pyroptosis, and translational assay design, beyond standard protocol guides.

• AM251: CB1 Receptor Antagonist for Translational Research

  2026-05-01

  AM251, a nanomolar-potency CB1 receptor antagonist, empowers precise modulation of endocannabinoid signaling in both neural and metabolic research. Its well-characterized pharmacology, robust solubility profile, and validated effects in vitro and in vivo make it indispensable for dissecting cannabinoid pathways, apoptosis, and cell cycle regulation.

16125 records 1/1075 page Next 12345 下5页 Last page